Intersect ENT To Present At The Canaccord Genuity Medical Technology & Diagnostics Forum

Intersect ENT, Inc. (NASDAQ:XENT) today announced that management will present an overview of the company's business at the 10 th Annual Canaccord Genuity Medical Technology & Diagnostics Forum.

The presentation is scheduled for 2:30pm ET on November 17, 2016, at the Westin Grand Central in New York City.

A replay of each presentation will be available via the investors section of the company's website at The webcast replays will be archived for approximately one month.

About Intersect ENT

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL ® and PROPEL ® Mini, which have been clinically proven to improve surgical outcomes for chronic sinusitis patients undergoing sinus surgery. In addition, Intersect ENT is developing a pipeline of steroid releasing implants designed to provide ENT physicians with options to treat patients across the continuum of care for chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition that can lead to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.

For additional information on the company or the products including risks and benefits please visit

INTERSECT ENT ® and PROPEL ® are registered trademarks of Intersect ENT, Inc.


View source version on

Copyright Business Wire 2010